Skip to main content
. 2017 May 25;8(31):51591–51607. doi: 10.18632/oncotarget.18196

Figure 10. GT198 vaccination suppresses mouse GL261 glioma growth.

Figure 10

(A) Immunohistochemical staining of GT198 in C57BL/6 mouse brain with GL261 glioma xenograft showing positive angiogenic vessels and tumor cells. Arrows indicate GT198+ cells. (B) Mice were vaccined by subcutaneous injection of recombinant GT198 protein as antigen (100 μg/injection) at indicated time points starting 6 weeks before GL261 tumor implantation. Tail blood serum (1:1000) from each bleed was analyzed for anti-GT198 antibody titer. One control and 4 vaccined mice are shown. (C) Kaplan-Meier curve analysis of mouse survival in control and vaccine groups (n=4) implanted with GL261. P and HR values are calculated by log-rank test. (D) Optical bioluminescent imaging of living mice at week 2 and week 3. (E) Tumor size as a function of GT198 antibody titer (log scale). Decreased tumor sizes, represented by photon intensity, are correlated with increased antibody titer particularly at the early stage in week 2.